Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Visualization of myelination in GFP-transgenic zebrafish.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
A full genome search in multiple sclerosis.
Withdrawal of the marketing authorization in the European Union
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo
Pharmacokinetics of CAMPATH-1H in BMT patients.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
One can prevent post-partum MS relapses by exclusive breast feeding: no.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.

Pages